US EPA

1455806 

Journal Article 

The proteomic study of sodium butyrate antiproliferative/cytodifferentiation effects on K562 cells 

Grebenova, D; Kuzelova, K; Pluskalova, M; Peslova, G; Halada, P; Hrkal, Z 

2006 

Yes 

Blood Cells Molecules and Diseases
ISSN: 1079-9796 

37 

3 

210-217 

English 

16978890 

10.1016/j.bcmd.2006.08.001 

WOS:000242432000011 

Employing methods of cell biology and proteome analysis tools, we examined effects of an inhibitor of histone deacetylases, sodium butyrate (SB), on the proliferation/differentiation characteristics of chronic myelogenous leukemia (CML)-derived cells K562. SB suppressed proliferation of K562 cells by inducing cell cycle arrest in G1 phase, which was followed by their transition to G0 phase (decrease of Ki-67 antigen-positive cells) and erythroid differentiation (increased glycophorin A expression and synthesis of hemoglobins). Neither terminal apoptosis (low counts of TUNEL-positive cells) nor necrosis (moderate counts of propidium iodide-positive cells) occurred. Importantly, SB attenuated protein expression of CML-related chimeric kinase BCR-ABL that is responsible for the deregulated proliferation of CML cells. The proteomic analysis (2-D electrophoresis combined with MALDI-TOF mass spectrometry and/or Western blotting) revealed several proteins that were differentially expressed or their mobility was altered due to butyrate treatment, namely, HSP90, HSP70, p23, cyclophilin A (CYPA), prefoldin2 (PFD2) and alpha-, gamma-, epsilon-human globin chains. Perturbation of HSP90 multichaperone complex of which BCR-ABL is the client protein is presumably a cause of BCR-ABL suppression. Changes in other proteins with chaperonic functions, CYPA and PFD2, may reflect SB antiproliferative and cytodifferentiation effects. 

K562; cell cycle; hemoglobin synthesis; BCR-ABL; proteome analysis; HSP90; p23; CYP-A; prefoldin2